No annual revenue total was found in AIMEI HEALTH TECHNOLOGY CO., LTD's SEC filings.
Aimei Health Technology Co., Ltd (AFJK) files with the SEC under industry code 6770, Blank Checks.
Revenue
—
Net income (TTM)
$412,432
-77.1% vs year-ago TTM
Operating cash flow (TTM)
$-370,854
+45.0% vs year-ago TTM
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
3.17M
-48.3% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Blank Checks (SIC 6770)
- Listed as
- AFJK (Nasdaq), AFJKR (Nasdaq), AFJKU (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1979005
Other Blank Checks companies
- Drugs Made In America Acquisition II Corp. DMII
- EQV Ventures Acquisition Corp. II EVAC
- Bain Capital GSS Investment Corp. BCSS
- Cantor Equity Partners IV, Inc. CEPF
- Churchill Capital Corp XII CXII
- American Exceptionalism Acquisition Corp. A AEXA
- New America Acquisition I Corp. NWAX
- Ares Acquisition Corp III AAC
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Operating income | -$835,759 | -$1.1M |
| Net income | $1.1M | $2.6M |
| Operating cash flow | -$565,100 | -$672,289 |
| Total assets | $12.1M | $73.8M |
| Total liabilities | $4.1M | $1.5M |
| Stockholders' equity | -$4.1M | -$1.5M |
| Cash and investments | $2,929 | $28,208 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
New debt
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K/A |
Amended current report
New debt
|
Nov 3, 2026 | Oct 5, 2026 |
| 8-K |
Current report
New debt
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
New debt
|
Sep 3, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 25, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
All 125 Aimei Health Technology Co., Ltd SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.